Wockhardt Ltd Stock Price Today (NSE: WOCKPHARMA)
Fundamental Score
Wockhardt Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Wockhardt Ltd share price today is ₹2022.80, up +5.40% on NSE/BSE as of 17 June 2026. Wockhardt Ltd (WOCKPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹23.95K (Cr). The 52-week high for WOCKPHARMA share price is ₹2422.30 and the 52-week low is ₹1086.70. At a P/E ratio of 436.52x, WOCKPHARMA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of -1.22% and a debt-to-equity ratio of 0.54.
Wockhardt Ltd Share Price Chart — NSE/BSE Historical Performance
Wockhardt Ltd share price chart: 15.44% return over the past month. 52-week high ₹2422.30, 52-week low ₹1086.70.
Wockhardt Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2140.00 | ₹2140.00 | ₹1940.00 | ₹1966.20 | 61.63L (Cr) | |
| ₹2377.00 | ₹2422.30 | ₹2126.40 | ₹2152.90 | 118.06L (Cr) | |
| ₹1925.00 | ₹2097.40 | ₹1872.10 | ₹2031.40 | 131.73L (Cr) | |
| ₹1771.00 | ₹1771.00 | ₹1771.00 | ₹1771.00 | 0.00 (Cr) | |
| ₹1716.00 | ₹1789.00 | ₹1706.00 | ₹1771.00 | 19.63L (Cr) | |
| ₹1646.00 | ₹1729.70 | ₹1633.60 | ₹1700.20 | 26.87L (Cr) | |
| ₹1591.60 | ₹1645.00 | ₹1571.00 | ₹1637.60 | 15.57L (Cr) | |
| ₹1605.00 | ₹1614.70 | ₹1569.00 | ₹1575.40 | 5.05L (Cr) | |
| ₹1618.00 | ₹1638.70 | ₹1594.60 | ₹1599.80 | 7.62L (Cr) | |
| ₹1623.60 | ₹1655.90 | ₹1601.10 | ₹1611.90 | 12.53L (Cr) |
Wockhardt Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2377.00 | ₹2422.30 | ₹1940.00 | ₹1966.20 | -17.28% | |
| ₹1395.60 | ₹2097.40 | ₹1395.60 | ₹2031.40 | +45.56% | |
| ₹1234.00 | ₹1532.00 | ₹1198.40 | ₹1395.60 | +13.10% | |
| ₹1310.00 | ₹1347.40 | ₹1086.70 | ₹1175.70 | -10.25% | |
| ₹1348.60 | ₹1463.00 | ₹1275.00 | ₹1361.90 | +0.99% | |
| ₹1438.00 | ₹1529.00 | ₹1335.00 | ₹1382.20 | -3.88% | |
| ₹1245.10 | ₹1566.90 | ₹1225.20 | ₹1446.20 | +16.15% | |
| ₹1290.40 | ₹1433.00 | ₹1230.00 | ₹1235.00 | -4.29% | |
| ₹1510.00 | ₹1524.00 | ₹1276.00 | ₹1281.50 | -15.13% | |
| ₹1427.50 | ₹1579.70 | ₹1325.00 | ₹1516.00 | +6.20% | |
| ₹1667.00 | ₹1676.70 | ₹1411.10 | ₹1427.50 | -14.37% | |
| ₹1715.10 | ₹1867.00 | ₹1645.20 | ₹1667.50 | -2.78% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Wockhardt Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Wockhardt Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of WOCKPHARMA across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Robust Profit Growth (454.55%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Risk Factors
8 factors identified
Below-Average Return on Equity (-1.22%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.75%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 436.52x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (1.15% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (1.37x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-535.25 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
High Share Pledging Risk (21.30%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Wockhardt Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Wockhardt Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Wockhardt LtdWockhardt Ltd...Selected✓ WOCKPHARMA • 532300 | 12.1/100 | ₹2022.80₹2023 | ₹23950.21₹23950.21 | 436.52Average 436.5 Average | -1.22%Poor -1.22% Poor | 3.75%Poor 3.75% Poor | 0.54Good 0.5 Good | 11.37%Good 11.37% Good | 1.15%Average 1.15% Average | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Wockhardt Ltd Dividend History
Annual cash dividends paid by WOCKPHARMA — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹2.00 Cr |
| FY 2021 | ₹1.00 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Wockhardt Ltd Quarterly Performance
Latest quarterly metrics for WOCKPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-3.34%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
454.55%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
1.15%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
11.37%
Compounded annual net profit growth over 5 years
Wockhardt Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for WOCKPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Wockhardt Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Wockhardt Ltd (WOCKPHARMA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Wockhardt Ltd
About WOCKPHARMA (Wockhardt Ltd)
Wockhardt Ltd is a global pharmaceutical force, weaving a legacy of scientific advancement and healthcare solutions across diverse geographies. From its roots in India, the company... has cultivated a robust presence in the United States, Europe, and beyond, establishing itself as a key player in the development, manufacturing, and marketing of a broad spectrum of pharmaceutical products. Wockhardt's commitment to innovation is evident in its pursuit of cutting-edge therapies and its unwavering dedication to improving patient outcomes worldwide. The company's expansive infrastructure and skilled workforce enable it to navigate the complexities of the global pharmaceutical landscape, ensuring the delivery of high-quality medicines to those in need. The company is deeply involved in crafting critical medicines that are delivered to the world's markets. In this arena, the organization is not just invested in established treatments. They are also committed to research and development of next generation solutions. It's research aims to address some of the most pressing health challenges. Wockhardt's R&D is designed to create solutions and treatments that improve health outcomes for people. This includes investment in advanced biotechnologies and novel drug delivery systems, showing a goal for progressive therapies and products. Wockhardt's product portfolio encompasses a wide array of therapeutic areas, and it has established a firm footprint in manufacturing and marketing complex generic formulations. The company maintains unwavering adherence to global regulatory standards and ethical practices, reflecting its commitment to patient safety and product integrity. With a focus on sustainability, Wockhardt endeavors to minimize its environmental impact while maximizing its positive contribution to society. Through strategic partnerships, collaborations, and a steadfast commitment to scientific excellence, Wockhardt continues to evolve as a dynamic and forward-thinking pharmaceutical organization, poised to shape the future of healthcare and deliver impactful solutions that improve lives around the world.
Company Details
Key Leadership
Corporate Events
WOCKPHARMA Share Price: Frequently Asked Questions
What is the current share price of Wockhardt Ltd?
Wockhardt Ltd (WOCKPHARMA) trades at ₹2022.80 on NSE and BSE. Market cap ₹23.95K (Cr). Educational data only.
What is the P/E ratio of Wockhardt Ltd?
Wockhardt Ltd has a P/E of 436.52x vs industry average 31.77x.
What is the Bull Run score for Wockhardt Ltd?
Wockhardt Ltd has a Bull Run score of 12.1/100 based on 25+ financial parameters.
Does Wockhardt Ltd pay dividends?
Wockhardt Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Wockhardt Ltd?
Wockhardt Ltd has ROE of -1.22%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Wockhardt Ltd?
Wockhardt Ltd has debt-to-equity of 0.54.
Is Wockhardt Ltd a good investment?
Bull Run gives Wockhardt Ltd a score of 12.1/100. This is not investment advice — consult a SEBI-registered advisor.